Evaluation of multigene assays as predictors for response to neoadjuvant chemotherapy in early-stage breast cancer patients

Jincong Q Freeman; Sarah Shubeck; Frederick M Howard; Nan Chen; Rita Nanda; Dezheng Huo

doi:10.1038/s41523-023-00536-z

Evaluation of multigene assays as predictors for response to neoadjuvant chemotherapy in early-stage breast cancer patients

NPJ Breast Cancer. 2023 May 6;9(1):33. doi: 10.1038/s41523-023-00536-z.

Authors

Jincong Q Freeman¹, Sarah Shubeck², Frederick M Howard³, Nan Chen³, Rita Nanda³, Dezheng Huo^{4

5}

Affiliations

¹ Department of Public Health Sciences, University of Chicago, Chicago, IL, USA.
² Department of Surgery, University of Chicago, Chicago, IL, USA.
³ Department of Medicine, Section of Hematology & Oncology, University of Chicago, Chicago, IL, USA.
⁴ Department of Public Health Sciences, University of Chicago, Chicago, IL, USA. [email protected].
⁵ Department of Medicine, Section of Hematology & Oncology, University of Chicago, Chicago, IL, USA. [email protected].

Abstract

OncotypeDX and MammaPrint assays have not been validated to predict pathologic complete response (pCR) to neoadjuvant chemotherapy (NACT) in early-stage breast cancer patients. We analyzed the 2010-2019 National Cancer Database and found that high OncotypeDX recurrence scores or high MammaPrint scores were associated with greater odds of pCR. Our findings suggest that OncotypeDX and MammaPrint testing predict pCR after NACT and could facilitate clinical decision-making between clinicians and patients.

Abstract

Grants and funding